Ferrokin brings in $8.4M for anemia treatment
Ferrokin Biosciences, a San Carlos Calif. company that makes compounds to treat iron overload in patients with anemia, received $8.4 million of what it hopes will be a $15 million first-round of funding from Clarus Ventures, Burrill & Co. and Celegene Inc.
Iron overload is a common side effect of repeated transfusions used to treat certain types of anemia. The company doesn’t have a website, and very little information on it is available.
Next Story: Twitter reports huge usage, no Fail Whales for Election Day
Previous Story: Web 2.0 Summit: Mary Meeker on how long the recession will last
Tags: co:Celegene, co:Ferrokin Biosciences, inv:Burrill-&-Co., inv:Clarus-Ventures
Camille is the lead writer for GreenBeat. She came to VentureBeat from Google where she worked on its traditional platforms team, particularly in TV. Before that, she was a reporter for the Wall Street Journal in New York and London. Follow her on Twitter at @camillericketts, and follow VentureBeat on Twitter at @venturebeat.
With GreenBeat 2009, VentureBeat's all-star conference on all things Smart Grid, coming up in November, Camille will be expanding coverage of this exciting space. Stay up to date by following @greenbeat2009 on Twitter or by becoming a fan of the event on Facebook here.